Oramorph

What Is Oramorph and What Is It Used For?

Oramorph contains the active substance morphine sulfate, a naturally occurring alkaloid derived from the opium poppy (Papaver somniferum) and the prototype of the strong opioid class. Morphine has been used in medicine since it was first isolated in 1804, and it remains the reference analgesic against which all other opioids are compared. It is listed by the World Health Organization (WHO) as an essential medicine for pain management and palliative care worldwide.

The 2 mg/ml oral solution formulation is an immediate-release (IR) preparation, meaning it acts rapidly and produces relatively short-lasting analgesia. This distinguishes it from long-acting (modified-release or sustained-release) morphine tablets and capsules, which provide background pain control over 12 to 24 hours. Because the liquid dose can be titrated precisely, Oramorph is particularly useful in patients who have difficulty swallowing tablets, in paediatric and geriatric care, and where fine dose adjustments are required.

Morphine works by binding to specific proteins called opioid receptors, most importantly the mu-opioid receptor (MOR), located in the brain, spinal cord, peripheral nerves, and gastrointestinal tract. Activation of these receptors reduces the transmission of pain signals from peripheral tissues to the brain and also alters the emotional response to pain. In addition to analgesia, morphine produces sedation, mood changes (euphoria or dysphoria), respiratory depression, pupillary constriction (miosis), slowed gastrointestinal transit (constipation), and suppression of the cough reflex.

Oramorph 2 mg/ml oral solution is indicated for the following clinical situations, in line with international guidelines from the WHO, the European Association for Palliative Care (EAPC), the UK National Institute for Health and Care Excellence (NICE), and the American Pain Society (APS):

• Moderate to severe cancer pain — as part of step 3 of the WHO analgesic ladder, either alone or in combination with long-acting morphine preparations
• Breakthrough pain in palliative care — transient flares of pain in patients already on background opioid therapy, where immediate-release morphine is titrated to the individual breakthrough dose
• Severe acute post-operative pain — as an oral alternative to parenteral opioids once the patient is able to swallow and pain is stabilising
• Severe chronic non-cancer pain — only when non-opioid analgesics and weaker opioids have failed, and under specialist pain management supervision
• Severe pain associated with myocardial infarction — in selected settings where intravenous access is unavailable
• Dyspnoea (breathlessness) in advanced cancer, heart failure or end-of-life care — where low-dose oral morphine has been shown to reduce the subjective sensation of breathlessness
• Intractable cough in advanced lung disease — as a palliative intervention under specialist supervision

It is important to understand that Oramorph is reserved for severe pain and is not a first-line treatment for mild or moderate pain that can be managed with non-opioid analgesics (such as paracetamol or non-steroidal anti-inflammatory drugs) or with weaker opioids (such as codeine or tramadol). The WHO analgesic ladder recommends a stepwise approach, moving to strong opioids like morphine only when weaker treatments are insufficient. The decision to start Oramorph involves a careful assessment of the balance between the expected benefit in pain relief and the risks of adverse effects, dependence, and misuse.

What Should You Know Before Taking Oramorph?

Before starting treatment with Oramorph, your doctor will carry out a detailed clinical assessment including your pain history, previous responses to analgesics, co-existing medical conditions, concurrent medications, and any history of substance use or mental health disorder. This assessment is essential because morphine is a powerful medicine with a narrow therapeutic window between effective pain relief and potentially fatal toxicity.

Contraindications

You must not take Oramorph if any of the following apply to you:

• Known hypersensitivity to morphine, other opioids, or any excipient — including true allergic reactions and severe pseudoallergic responses such as angioedema or bronchospasm
• Acute respiratory depression or respiratory failure of any cause — morphine further depresses the respiratory drive and can rapidly precipitate apnoea
• Severe chronic obstructive pulmonary disease (COPD) with hypercapnia, or acute asthma attack — use requires specialist supervision
• Paralytic ileus or any condition in which gastrointestinal motility is severely impaired
• Acute abdomen — morphine can mask symptoms and delay diagnosis
• Acute liver disease or severe hepatic impairment — morphine metabolism and clearance are markedly reduced
• Concurrent use of monoamine oxidase inhibitors (MAOIs) — or within 14 days of stopping an MAOI, due to risk of severe hypertensive or CNS reactions
• Raised intracranial pressure or head injury — morphine can cause further CO₂ retention and worsen cerebral oedema, and miosis may obscure neurological assessment
• During labour, in the preterm period, or when delivery is expected — due to risk of neonatal respiratory depression
• Coma or severely reduced level of consciousness
• Acute alcohol or sedative intoxication
• Phaeochromocytoma — due to risk of opioid-induced catecholamine release

Warnings and Precautions

Exercise particular caution and discuss fully with your doctor if you have any of the following conditions, which may require dose reduction, closer monitoring, or an alternative analgesic:

• History of substance-use disorder, including alcohol dependence — increased risk of opioid use disorder; close monitoring and risk-mitigation strategies are recommended
• Elderly or debilitated patients — more sensitive to respiratory depression, sedation, and confusion; start at the lowest effective dose
• Moderate renal impairment — the active metabolite morphine-6-glucuronide accumulates and can cause prolonged sedation and respiratory depression
• Moderate hepatic impairment — reduced clearance may require dose reduction and longer dosing intervals
• Hypothyroidism, adrenal insufficiency (Addison’s disease), or prostatic hypertrophy — increased sensitivity to opioid effects
• Biliary tract disease or pancreatitis — morphine can cause spasm of the sphincter of Oddi and raise biliary pressure
• Inflammatory or obstructive bowel disorders — opioid-induced reduction in motility can worsen the condition
• Convulsive disorders — morphine may lower the seizure threshold
• Sleep apnoea or severe snoring — increased risk of central respiratory depression during sleep
• Recent abdominal surgery or ileus risk — use the lowest effective dose and monitor bowel function
• Mental health disorders, including depression, anxiety or psychosis — careful assessment of opioid use disorder risk
• Driving or operating machinery — Oramorph can cause drowsiness and impaired reaction time; patients should not drive until they know how the medicine affects them

Pregnancy and Breastfeeding

Pregnancy. Morphine crosses the placenta, and its use during pregnancy should be limited to situations where the benefit clearly outweighs the risks. Short-term use in early pregnancy at recommended analgesic doses has not been consistently associated with major congenital malformations, but data remain limited. Regular or prolonged use, particularly in the third trimester, can cause neonatal opioid withdrawal syndrome (NOWS), characterised by irritability, high-pitched crying, tremors, poor feeding, diarrhoea, sweating, and seizures, which may require specialist neonatal care. Use close to delivery can cause respiratory depression in the newborn. The European Medicines Agency (EMA) and the UK BNF advise that Oramorph should be used during pregnancy only under specialist supervision.

Labour. Oramorph is contraindicated during labour because it can cause respiratory depression in the neonate. If an opioid analgesic is required, parenteral agents with established obstetric safety profiles and close fetal monitoring are generally preferred.

Breastfeeding. Morphine and its active metabolite M6G pass into breast milk in small amounts. Occasional short-term use at low maternal doses may be acceptable, but regular or high-dose use during breastfeeding is generally not recommended, as cumulative exposure can cause sedation, feeding difficulties and apnoea in the breastfed infant. Infants whose mothers take morphine should be monitored for drowsiness, breathing problems, and poor feeding. Mothers should always discuss breastfeeding with their healthcare team when taking opioids.

Children and Adolescents

Oramorph can be used in children and adolescents for severe pain (e.g., cancer pain, post-operative pain) under specialist supervision, with weight-based dosing. It is not recommended in children under 1 year outside of specialist settings, and extra caution is required in any child with respiratory disease, sleep apnoea, or recent adenotonsillectomy for obstructive sleep apnoea. The risk of fatal respiratory depression is particularly increased in these groups. All paediatric doses must be calculated per kilogram of body weight and checked by a second healthcare professional.

Elderly Patients

Older adults are more susceptible to all opioid adverse effects, including sedation, confusion, respiratory depression, constipation, urinary retention, and falls. Age-related decline in renal function enhances accumulation of active metabolites. Starting doses should be reduced (typically by 25–50% compared with younger adults), dosing intervals may need to be longer, and therapy should be reviewed frequently. Concurrent use of other centrally acting medications (benzodiazepines, antipsychotics, anticholinergics) should be minimised.

How Does Oramorph Interact with Other Drugs?

Drug interactions are a major consideration when prescribing Oramorph. Morphine is metabolised primarily by the hepatic UDP-glucuronosyltransferase enzyme UGT2B7, so interactions with classical cytochrome P450 inducers or inhibitors are less prominent than with some other opioids. However, pharmacodynamic interactions — the combined effects on the central nervous system, respiration, and the gut — are frequent and clinically significant. The tables below summarise the most important interactions grouped by severity.

Major Interactions

Minor Interactions

This list is not exhaustive. Because Oramorph is often used in patients with complex medical conditions and polypharmacy, a full medication review — including over-the-counter products, herbal remedies (e.g., St John’s wort, kava, valerian), and recreational substances — should be performed before starting treatment and whenever a new medication is added. Always inform every healthcare professional involved in your care that you are taking Oramorph.

What Is the Correct Dosage of Oramorph?

Oramorph dosing must be carefully individualised to the patient’s pain intensity, body weight, age, renal and hepatic function, opioid tolerance, and the specific clinical situation. The 2 mg/ml concentration means that 1 ml of solution contains 2 mg of morphine sulfate. Doses should always be measured with the graduated oral syringe or measuring spoon provided — never with a household teaspoon, which is inaccurate and can lead to dangerous errors.

Adults

Children

Paediatric dosing is weight-based and must be calculated and double-checked by trained clinicians. Typical oral morphine starting doses for severe pain (adapted from WHO guidelines):

• Infants 1–12 months: 80–200 micrograms/kg every 4 hours (specialist supervision only)
• Children 1–12 years: 200–300 micrograms/kg every 4 hours; maximum single dose typically 10 mg
• Adolescents 12–18 years: 5–10 mg every 4 hours, up to adult doses

Infants under 1 year should receive morphine only under specialist care due to immature metabolism and increased risk of respiratory depression. The 2 mg/ml concentration is particularly suitable for paediatric use because small volumes can be accurately measured.

Elderly

In older adults (generally over 65 years, or frail adults over 50), initial doses should be reduced by approximately 25–50% compared with younger adults. A common starting regimen is 2.5–5 mg (1.25–2.5 ml) every 4–6 hours, titrated carefully. Consider longer dosing intervals in renal impairment, and proactively prescribe laxatives to prevent constipation, which is universal with opioid therapy.

Patients with Renal or Hepatic Impairment

Renal impairment. Morphine-6-glucuronide (M6G), an active metabolite, is eliminated by the kidneys and accumulates when renal function declines. In moderate to severe renal impairment, start at lower doses with extended intervals (e.g., every 6–8 hours) or consider an alternative opioid with a better renal profile (e.g., fentanyl or buprenorphine), particularly in end-stage renal disease.

Hepatic impairment. In moderate hepatic impairment, morphine clearance is reduced and its half-life is prolonged. Dose reduction and longer intervals between doses are required, with careful monitoring for sedation. Severe hepatic impairment is generally a contraindication for Oramorph outside specialist settings.

Missed Dose

If Oramorph has been prescribed at regular scheduled intervals for chronic pain: take the missed dose as soon as you remember, unless it is almost time for the next scheduled dose. In that case, skip the missed dose and continue with your normal schedule. Never take two doses close together or a double dose to “catch up”, as this can cause dangerous overdose.

If Oramorph has been prescribed “as needed” (PRN) for breakthrough pain: there is no need to catch up on missed doses. Take Oramorph only when you genuinely have pain and observe the minimum interval between doses specified by your prescriber (usually at least 1 hour).

Overdose

Morphine overdose is a medical emergency and can be fatal without prompt treatment. The classical opioid overdose triad consists of:

• Pinpoint (miotic) pupils
• Respiratory depression — slow, shallow, irregular, or absent breathing (often <12 breaths per minute)
• Reduced level of consciousness — ranging from severe drowsiness to coma

Other signs include limp muscle tone, cold and clammy skin, bluish or greyish discolouration of the lips and fingertips (cyanosis), hypotension, bradycardia, gurgling or choking sounds, pulmonary oedema, and seizures. Overdose can develop rapidly, particularly when Oramorph has been combined with alcohol, benzodiazepines, or other sedatives.

What to do if overdose is suspected:

1. Call emergency services immediately (112 in Europe, 999 in the UK, 911 in the US).
2. If available and you are trained, administer naloxone (intranasal or intramuscular) according to local protocols. Naloxone is a specific opioid antagonist that reverses respiratory depression. Its effect is short (30–60 minutes), so repeat doses may be needed until professional help arrives.
3. Place the person in the recovery position if unconscious but breathing.
4. Begin rescue breathing (or CPR if there is no pulse) if breathing has stopped.
5. Stay with the person until emergency services arrive; morphine’s effect is longer than that of naloxone and re-sedation is common.

What Are the Side Effects of Oramorph?

Like all strong opioids, Oramorph causes predictable side effects that reflect the wide distribution of opioid receptors in the body. Some side effects (such as constipation) persist throughout treatment, while others (such as nausea and drowsiness) tend to improve after the first few days as tolerance develops. The frequencies below are based on European product information and large clinical studies, following MedDRA conventions.

If you experience any of the following, stop taking Oramorph and seek medical help immediately: very slow or shallow breathing, extreme drowsiness or inability to stay awake, bluish lips or fingertips, severe confusion or hallucinations, severe allergic reaction (swelling of face/throat, difficulty breathing), seizures, or features of serotonin syndrome (agitation, fever, sweating, tremor, muscle twitching, rapid heart rate). These symptoms may indicate a life-threatening reaction that requires urgent emergency care.

Managing predictable side effects. Constipation should be anticipated and prevented from day one with a stimulant laxative (e.g., senna) with or without a softener (e.g., docusate). Osmotic laxatives (macrogol, lactulose) can be added as needed. Nausea is typically self-limiting within 3–5 days but can be treated with an antiemetic such as metoclopramide, haloperidol (in palliative care), or ondansetron for short periods. Drowsiness usually improves within the first week; if it persists or is severe, the dose may need to be reduced or the opioid rotated.

Can Oramorph Cause Tolerance, Dependence, or Withdrawal?

Tolerance is the need for progressively higher doses of an opioid to achieve the same analgesic or side-effect response. It typically develops over days to weeks of regular use and affects most opioid effects (sedation, respiratory depression, euphoria) but rarely constipation or miosis. In pain management, increasing pain relief requirements may also reflect progression of the underlying condition (e.g., advancing cancer), not true pharmacological tolerance alone.

Physical dependence is a predictable physiological adaptation in which the body becomes accustomed to the presence of opioids and responds with a characteristic withdrawal syndrome if the drug is abruptly stopped or reversed with an antagonist. It is not the same as addiction; physical dependence occurs in virtually all patients on regular opioids for more than a few weeks, and it does not imply misuse. Addiction (opioid use disorder) is a distinct condition characterised by compulsive drug-seeking behaviour and continued use despite harm, and is uncommon but not rare in patients on long-term prescription opioids.

Opioid withdrawal syndrome typically begins within 6–24 hours after the last dose of morphine and peaks at 24–72 hours. Symptoms include yawning, runny nose, tearing eyes, sweating, piloerection (“gooseflesh”), hot and cold flushes, muscle and joint aches, abdominal cramps, diarrhoea, nausea, vomiting, restlessness, anxiety, insomnia, tachycardia, hypertension, and dilated pupils. Withdrawal is very unpleasant but not life-threatening in otherwise healthy adults, although it can be dangerous in frail patients, pregnant women, and newborns.

Tapering. After more than a few weeks of regular Oramorph use, the dose should be reduced gradually under medical supervision. A common approach is to reduce the total daily dose by 10–25% every 1–2 weeks, with slower reductions at lower doses. Symptom-guided tapering allows adjustment based on withdrawal and pain control. In specialist settings, opioid rotation to buprenorphine or methadone and the use of adjuncts (clonidine, lofexidine, antiemetics, loperamide) can support the tapering process.

How Should You Store Oramorph?

Because Oramorph is a controlled drug and a potent opioid, safe storage at home is critical. Accidental ingestion by a child, pet, or person without opioid tolerance can be fatal. Regulatory agencies worldwide strongly recommend that patients and caregivers store Oramorph securely and account for each dose.

• Temperature. Store below 25°C (77°F). Do not refrigerate or freeze, as this may affect the stability of the oral solution and lead to crystallisation. Avoid places with temperature extremes (near radiators, in direct sunlight, in a hot car, or in a humid bathroom).
• Container. Keep the bottle tightly closed and upright in the original packaging to protect from light. The cap is often child-resistant; ensure it is fully closed after each use.
• Shelf life after opening. Once the bottle has been opened, Oramorph should be used within the period specified on the product information leaflet (typically 90 days for the 2 mg/ml concentration). Write the date of opening on the bottle and discard any solution remaining after this period.
• Secure storage. Store Oramorph in a locked cabinet or medicine lockbox if there are children, adolescents, or people with a history of substance use disorder in the household. Never leave the bottle on a bedside table or in a bag where it could be accessed by others.
• Expiry date. Do not use Oramorph after the expiry date printed on the packaging. The expiry date refers to the last day of that month.
• Accurate measurement. Always use the measuring device (oral syringe or graduated spoon) supplied with the product. Do not use a household teaspoon, as this can result in dangerous overdose.
• Disposal of unused medicine. Return any unused Oramorph to your pharmacy or an authorised take-back scheme for safe destruction. Do not flush down the toilet, pour down the sink, or place in general household waste — opioid medicines can contaminate water supplies and be diverted for misuse.

If the solution has changed colour, become cloudy, developed an unusual smell, or if the bottle has been damaged, do not use it. Contact your pharmacist for advice on replacement and disposal.

What Does Oramorph Contain?

Knowing the full composition of your medicine is important, particularly if you have allergies, intolerances, or specific dietary needs (e.g., diabetes, gluten-free, alcohol-free). Each 1 ml of Oramorph 2 mg/ml oral solution contains the following:

Active Ingredient

• Morphine sulfate pentahydrate 2 mg per ml — the pharmacologically active component responsible for the analgesic effect.

Excipients (Inactive Ingredients)

The excipients give the solution its taste, physical stability, and shelf life. The exact composition varies between manufacturers, but commonly includes:

• Purified water — the solvent base for the oral solution
• Hydroxybenzoates (parabens) or sodium benzoate — preservatives that prevent microbial growth in the open bottle
• Citric acid monohydrate or sodium citrate — buffer to stabilise pH and maintain drug solubility
• Sucrose, sorbitol or liquid maltitol — sweeteners that improve palatability; patients with fructose intolerance, diabetes, or who follow sugar-restricted diets should check the specific formulation
• Flavourings — commonly cherry, raspberry or strawberry
• Colouring agents — some formulations are coloured, others are clear and colourless
• Ethanol (alcohol) — small amounts may be present in some formulations as a co-solvent; patients avoiding alcohol for religious, medical, or recovery-related reasons should check the specific product leaflet

If you have known hypersensitivity to parabens, benzoates, sulphites, or any flavouring/colouring, ask your pharmacist for the specific excipient list of the formulation you have been prescribed and consider alternative opioid preparations if needed. Patients with fructose intolerance should avoid formulations containing sucrose or sorbitol. In many countries, a sugar-free, alcohol-free version is also available for paediatric, diabetic, and dental applications.

Oramorph is marketed in several bottle sizes (typically 100 ml and 500 ml), often with an integrated graduated oral syringe (1 ml, 2 ml, or 5 ml). The 2 mg/ml concentration should not be confused with the stronger 20 mg/ml oral morphine solution (also marketed as Oramorph in some countries), which is used in opioid-tolerant patients for cancer and palliative care. Always check the strength on the label before every dose.